BREAST CANCER | LUNG CANCERS | COLON CANCER | PANCREATIC CANCER | RENAL CELL CANCER | LEUKEMIA – CML | LYMPHOMA’S | MULTIPLE MYELOMA | MYELODYSPLASTIC SYNDROME | MYELOPROLIFERATIVE NEOPLASMS | THROMBOCYTOPENIA – ITP | PNH – PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | SHINGLES PREVENTION
Neo-Adjuvant or Adjuvant
A Pivotal Study in Breast Cancer patients Investigating efficacy and safety of LA-EP2006 and Neulasta.
Metastatic 1st Line
A Phase III, Randomized, Double –Blind, Placebo-Controlled, Mulitcenter Study to Evaluate the Efficacy and Safety of Bevacizumab and Associated Biomarkers in Combination with Paclitaxel in Comparison with Paclitaxel Plus Placebo as First Line Treatment of Pts with Her 2 Negative Breast Cancer.
Extensive Stage Metastatic 1st line
A Randomized, Multicenter, Double –Blind, Phase III Trial Comparing the Efficacy of Ipilumumab Plus Etoposide/Platinum versus Placebo plus Etposide/Platinum in Subjects with Newly Diagnosed Extensive Stage Disease Small Cell Lung Cancer ( ED-SCLC )
Advanced or Metastatic 1st Line
A Randomized, Double – Blind, Multicenter, Phase II Trial Comparing Veliparib Plus Carboplatin and Paclitaxel versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non Small Cell Lung Cancer (NSCLC).
An Open-Label, Multicenter, Randomized, Phase II Study of Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, Mab-V in Combination with Platinum Based Chemotherapy vs. Platinum Based Chemotherapy Alone as First Line Treatment of pts with recurrent or Advanced Non Small Cell Lung Cancer
A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Alone in the
First–Line treatment of Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
A Phase III, Open-Label, Randomized, Multicenter, Study of Imprime PGG, in Combination with Cetuximab, (Erbitux) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer.
Advanced Disease 2nd Line
A Phase II Study of STA – 9090 as Second Line Therapy for Metastatic Pancreatic Cancer
A Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
A Single Arm, Open Label, Multi-Center Study of Complete Molecular Response (CMR) in Adult Patients with NEWLY DIAGNOSED Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase
Relapsed or Refractory
A Randomized, Multicenter, Study Comparing Pixantrone + Rituximab or Gemcitabine + Rituximab, in Non Stem Cell Transplant Eligible Patients with Aggressive B-Cell Non-Hodgkins Lymphoma who have Relapsed after Therapy with CHOP-R or Equivalent Regimen.
Relapsed or Refractory, 2n, 3rd, or 4th Line txt
A Phase III, Randomized, Double Blind, Multicenter, Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone vs. Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or refractory Multiple Myeloma
Micro RNA’s in Myelodysplastic Syndrome – to determine the contribution of hypermethylation in the dysregulation of miRNA expression in MDS; also to determine if treatment with DNMTI’s (DNA Methyltransferase Inhibitors) corrects the expression changes in miRNAs as associated with MDS – ( VICCAN HEM – 1137 )
A Phase II Study of LY2784544 in patients with Myeloproliferative Neoplasms – Polycythemia Vera, Essential Thrombocytopenia, or Myelofibrosis.
A Phase III, Multicenter, Randomized , Double-Blind, Active Controlled Parallel Group Trial with an Open-Label Extension Phase to Evaluste the Efficacy and Safety of Oral E5501 vs. Eltrombopag, in Adults with Chronic Immune Thrombocytopenia. ( Idiopathic Thrombocytopenic Purpura )
The PNH Registry is a prospective, multi-center, multi-national, observational registry compiling data on the natural history and management of subjects diagnosed with PNH
A Phase II Randomized, Placebo-Controlled, Clinical trial to Study the Safety and Efficacy of V212 (Inactivated Varicella-Zoster Virus Vaccine) in Adult Patients with Solid Tumor or Hematologic Malignancy.